syn-004
Generic: ribaxamase·Code: SYN-004
syn-004: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Theriva Biologics, Inc. (TOVX) | Phase 1/Phase 2 |
Clinical Trials (1)
Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients
Frequently asked questions
Who is developing syn-004?
syn-004 is being developed by Theriva Biologics, Inc..
How many clinical trials involve syn-004?
BioSniper tracks 1 clinical trial involving syn-004.
Get deeper analysis on syn-004
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis